NEW YORK (GenomeWeb News) – Synthetic biology firm Gen9 has raised $395,000 toward a $2 million round, the company said in a regulatory document filed Tuesday.

In its Form D filed with the US Securities and Exchange Commission, the Cambridge, Mass.-based firm said that the funds raised were in the form of debt. Kevin Munnelly, its president and chief business officer, told GenomeWeb Daily News in an e-mail today that proceeds will be used to commercialize the company's products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.